Edwards Lifesciences Corp (EW)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $61.61B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edwards Lifesciences Corp (EW) Financials: Revenue, Profit and Cash Flow
Edwards Lifesciences reported revenue of $6.07B for the fiscal year ended Dec 31, 2025, up 11.5% from the year before. That year, net income was $1.07B with a net margin of 17.6%, operating cash flow was $1.60B and free cash flow was $1.33B. The quarter ended Sep 30, 2026 had revenue of $1.72B and net income of $301.40M.
Revenue and Margins
The operating margin was 20.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.96B, a compound annual rate of 8.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $6.07B | +11.5% | 78.0% | 20.8% | 17.6% |
| Dec 2024 | $5.44B | +8.6% | 79.5% | 25.3% | 76.7% |
| Dec 2023 | $5.01B | +12.2% | 80.5% | 26.1% | 27.9% |
| Dec 2022 | $4.46B | -14.7% | 83.8% | 33.6% | 34.1% |
| Dec 2021 | $5.23B | +19.3% | 76.1% | 32.3% | 28.7% |
| Dec 2020 | $4.39B | +0.9% | 75.4% | 20.5% | 18.8% |
| Dec 2019 | $4.35B | +16.8% | 74.4% | 26.4% | 24.1% |
| Dec 2018 | $3.72B | +8.4% | 74.8% | 20.1% | 19.4% |
| Dec 2017 | $3.44B | +15.9% | 74.5% | 31.7% | 17.0% |
| Dec 2016 | $2.96B | N/A | 73.1% | 25.3% | 19.2% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 74.3% from the year before. In the quarter ended Sep 2026, net income rose 3.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B |
| Cost of revenue | $1.33B | $1.12B | $978.40M | $723.70M | $1.25B | $1.08B | $1.11B | $939.40M | $875.30M | $797.40M |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B |
| Research and development | $1.08B | $1.05B | $962.90M | $843.60M | $903.10M | $760.70M | $752.70M | $622.20M | $552.60M | $442.20M |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $897.60M | $1.15B | $748.20M | $1.09B | $751.20M |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $823.40M | $1.05B | $722.20M | $583.60M | $569.50M |
| EBITDA | $1.28B | $1.60B | $1.47B | $1.64B | $1.84B | $1.02B | $1.27B | $836.70M | $1.12B | $817.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.72B | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B |
| Gross profit | $1.35B | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870.10M |
| Operating income | $299.10M | $513.20M | $477.60M | $151.10M | $307.10M | $411.20M | $394.80M | $312.60M | $350.60M | $366.50M | $349.00M | $291.10M |
| Net income | $301.40M | $241.40M | $380.70M | $91.20M | $290.30M | $331.50M | $356.40M | $384.30M | $3.07B | $365.00M | $351.00M | $369.70M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $622.80M by $2.32B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B |
| Current assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B |
| Cash and equivalents | $2.94B | $3.05B | $1.13B | $769.00M | $862.80M | $1.18B | $1.18B | $714.10M | $818.30M | $930.10M |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | $2.34B | $2.18B | $2.71B | $1.89B |
| Short-term debt | $24.50M | $23.40M | $22.90M | $25.50M | $25.50M | $27.20M | $25.50M | $0 | $649.70M | $0 |
| Long-term debt | $598.30M | $597.70M | $597.00M | $596.30M | $595.70M | $595.00M | $594.40M | $593.80M | $438.40M | $822.30M |
| Shareholder equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $14.14B | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | $9.36B |
| Total liabilities | $3.18B | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | $2.64B |
| Cash and equivalents | $3.11B | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | $1.13B |
| Shareholder equity | $10.86B | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | $6.65B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 83.1% of operating cash flow. Share repurchases came to 67.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.60B | $542.30M | $895.80M | $1.22B | $1.73B | $1.05B | $1.18B | $926.70M | $1.00B | $704.40M |
| Capital expenditures | $260.20M | $252.40M | $253.00M | $244.60M | $325.80M | $407.00M | $254.40M | $238.70M | $168.10M | $176.10M |
| Free cash flow | $1.33B | $289.90M | $642.80M | $973.60M | $1.41B | $647.30M | $928.50M | $688.00M | $832.60M | $528.30M |
| Dividends paid | N/A | N/A | $169.90M | $146.40M | $158.60M | $140.50M | $18.90M | $688.00M | $0 | $253.50M |
| Share repurchases | $893.40M | $1.16B | $879.60M | $1.73B | $512.80M | $625.40M | $263.30M | $795.50M | $763.30M | $662.30M |
| Investing cash flow | -$712.90M | $2.31B | $173.80M | $252.30M | -$1.72B | -$531.10M | -$595.80M | $76.70M | -$647.20M | -$211.70M |
| Financing cash flow | -$956.80M | -$983.00M | -$711.00M | -$1.58B | -$356.30M | -$486.90M | -$115.60M | -$1.10B | -$473.20M | -$268.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $570.30M | $651.90M | $43.80M | $450.90M | $573.70M | $290.20M | $280.40M | -$127.50M | $351.80M | $371.50M | -$53.50M | $136.60M |
| Capital expenditures | $63.60M | $66.90M | $64.90M | $97.40M | $57.50M | $49.30M | $56.00M | $49.80M | $51.90M | $85.40M | $65.30M | $88.30M |
| Free cash flow | $506.70M | $585.00M | -$21.10M | $353.50M | $516.20M | $240.90M | $224.40M | -$177.30M | $299.90M | $286.10M | -$118.80M | $48.30M |
Frequently Asked Questions About EW
What is Edwards Lifesciences' annual revenue?
Edwards Lifesciences reported revenue of $6.07B for the fiscal year ended Dec 31, 2025.
How fast is Edwards Lifesciences' revenue growing?
Revenue was up 11.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.8%.
Is Edwards Lifesciences profitable?
Yes. Edwards Lifesciences reported net income of $1.07B for the fiscal year ended Dec 31, 2025, with a net margin of 17.6%.
How much free cash flow does EW generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.60B minus capital expenditures of $260.20M produced free cash flow of $1.33B.
How much debt does Edwards Lifesciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $598.30M, short-term debt of $24.50M and cash and equivalents of $2.94B.
EW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts